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WNT/b-catenin pathway activation in Myc immortalised
cerebellar progenitor cells inhibits neuronal differentiation
and generates tumours resembling medulloblastoma
HA Rogers*,1, S Sousa2, C Salto2, E Arenas2, B Coyle1 and RG Grundy1
1Children’s Brain Tumour Research Centre, Queen’s Medical Centre, University of Nottingham, D Floor Medical School, Nottingham NG7 2UH, UK;
2Laboratory of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
BACKGROUND: Medulloblastoma is the most common malignant childhood brain tumour. Aberrant activation of the WNT/b-catenin
pathway occurs in approximately 25% of medulloblastomas. However, its role in medulloblastoma pathogenesis is not understood.
METHODS: We have developed a model of WNT/b-catenin pathway-activated medulloblastoma. Pathway activation was induced in a
Myc immortalised cerebellar progenitor cell line through stable expression of Wnt1. In vitro and in vivo analysis was undertaken to
understand the effect of pathway activation and identify the potential cell of origin.
RESULTS: Tumours that histologically resembled classical medulloblastoma formed in vivo using cells overexpressing Wnt1, but not with
the control cell line. Wnt1 overexpression inhibited neuronal differentiation in vitro, suggesting WNT/b-catenin pathway activation
prevents cells terminally differentiating, maintaining them in a more ‘stem-like’ state. Analysis of cerebellar progenitor cell markers
demonstrated the cell line resembled cells from the cerebellar ventricular zone.
CONCLUSION: We have developed a cell line with the means of orthotopically modelling WNT/b-catenin pathway-activated
medulloblastoma. We provide evidence of the role pathway activation is playing in tumour pathogenesis and suggest
medulloblastomas can arise from cells other than granule cell progenitors. This cell line is a valuable resource to further understand
the role of pathway activation in tumorigenesis and for investigation of targeted therapies.
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The most common solid tumours during childhood are those
arising in the central nervous system (CNS). Medulloblastomas
occur in the cerebellum and are the most common malignant
paediatric brain tumours (Ellison, 2002). Over recent years,
treatments have improved with 5-year survival rates for patients
with medulloblastoma of 60–70% (Louis et al, 2007). However, one
third of patients still die and many surviving patients suffer long-
term side effects from treatments (Gilbertson and Ellison, 2008).
Recent expression array studies have identified subgroups of
medulloblastoma associated with different molecular pathways
(Thompson et al, 2006; Kool et al, 2008; Northcott et al, 2011).
One subgroup was characterised by aberrant activation of the WNT/
b-catenin pathway. Additional studies have identified WNT/b-
catenin pathway activation in 25% medulloblastomas with the
majority associated with activating mutations in b-catenin (Ellison
et al, 2005; Clifford et al, 2006; Gajjar et al, 2006; Rogers et al, 2009).
Pathway activation has also been shown to be associated with a
better clinical outcome (Ellison et al, 2005; Gajjar et al, 2006).
The WNT/b-catenin pathway plays a key role in many cellular
functions related to tumorigenesis including cell proliferation,
migration and differentiation. b-Catenin is the key downstream
effecter. When the pathway is inactive, b-catenin is bound to a
cytoplasmic complex containing adenomatous polyposis coli,
axin1 and glycogen synthase kinase 3b. Glycogen synthase kinase
3b phosphorylates b-catenin which targets the protein for
degradation through the ubiquitin-proteasome system (Morin,
1999). Upon pathway activation, the cytoplasmic complex is
inhibited stabilising b-catenin and allowing it to translocate to the
nucleus where it acts as a transcriptional cofactor of TCF and LEF
and leads to the transcription of target genes including myc (MYC)
and cyclin D1 (CCND1) (He et al, 1998; Tetsu and McCormick,
1999). In the majority of medulloblastoma cases, WNT/b-catenin
pathway activation is caused by mutations in b-catenin that are
thought to disrupt the phosphorylation sites that target the protein
for degradation (Ellison et al, 2005; Clifford et al, 2006; Gajjar et al,
2006).
The WNT/b-catenin pathway plays a key role in CNS develop-
ment including the cerebellum. Loss of Wnt1 or b-catenin in
mouse models caused severe abnormalities in midbrain and
cerebellar development by preventing specification of the
midbrain–hindbrain boundary (McMahon and Bradley, 1990;
Thomas and Capecchi, 1990; Schuller and Rowitch, 2007). The
pathway also regulates stem cell proliferation (Chenn and Walsh,
2002; Israsena et al, 2004), and the balance between progenitor cell
expansion and differentiation (Zechner et al, 2003).
The cell of origin of medulloblastoma has long been debated.
Cerebellar neurons are generated from two progenitor cell zones,
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the cerebellar ventricular zone (VZ) and the rhombic lip (RL)
(Millen and Gleeson, 2008). Granule neurons originate from the
RL. The majority of other cerebellar neurons, as well as glial cells,
originate from the VZ (Hatten and Roussel, 2011). Medulloblas-
tomas were thought to arise from progenitors of granule neurons
found in the external granule layer of the cerebellum (Louis et al,
2007). However, researchers have suggested that different subtypes
of medulloblastoma arise from distinct progenitor cells, with
WNT/b-catenin pathway subgroup tumours originating from
progenitor cells in the VZ (Katsetos et al, 1995; Louis et al, 2007;
Gilbertson and Ellison, 2008; Sutter et al, 2010). In a recent study
by Gibson et al (2010), tumours were generated from dorsal brain
stem progenitor cells in the lower RL in a mouse model of WNT/b-
catenin pathway associated medulloblastoma.
The biological effect of WNT/b-catenin pathway activation in
medulloblastoma is unknown. Pathway activation has been
associated with a better prognosis, which could suggest activation
is a disadvantage for the tumour. However, it seems unlikely a
tumour would retain cells with an activating mutation unless it
played some role in tumorigenesis. We hypothesised that pathway
activation plays a fundamental role in tumorigenesis. To under-
stand the role of WNT/b-catenin pathway activation in medullo-
blastoma, we stably expressed Wnt1, to activate the WNT/b-
catenin pathway, in Myc immortalised cerebellar progenitor cells
(Snyder et al, 1992). We show that WNT/b-catenin pathway
activation enables tumours to form in vivo and propose that WNT/
b-catenin pathway does this by inhibiting the ability of the cells to
differentiate, thereby maintaining them in their proliferative state.
We found expression of nerve growth factor receptor (NGFR) was
downregulated in the Wnt1-expressing cell line. Signalling through
NGFR, by nerve growth factor (NGF), can induce neuronal
differentiation, suggesting downregulation of NGFR expression
could be one mechanism by which WNT/B-catenin pathway
activation inhibited differentiation. Analysis of cerebellar progeni-
tor cell markers suggested the C17.2 line did not resemble granule
cell progenitors, supporting evidence that medulloblastomas with
WNT/b-catenin pathway activation do not originate from the
external granule layer.
MATERIALS AND METHODS
Stable cell line generation
The pCA-EGFP vector was used to generate a Wnt1 expression
clone. EGFP was removed and Wnt1 cDNA was cloned into the
vector. The C17.2 cell line generated from mouse cerebellar
progenitor cells (Snyder et al, 1992) was stably transfected with the
Wnt1 expression construct. Cells expressing Wnt1 were selected
using 2mgml 1 of zeocin (Invitrogen, Carlsbad, CA, USA).
Cell culture conditions
C17.2 cells were cultured in standard humidified incubators at
5% CO2 in Dulbecco’s modified Eagle’s medium/L-glutamine
(Invitrogen) supplemented with 10% fetal bovine serum
(PAA Laboratories, Yeovil, UK), 5% horse serum (Invitrogen)
and antibiotics. Under differentiation conditions, the media above
was replaced with neurobasal medium (Invitrogen) containing B27
supplement (Invitrogen), 2mM L-glutamine (Sigma-Aldrich, Poole,
UK) and NGF (Millipore, Watford, UK) at a final concentration of
200 ngml 1. For the Wnt1 stable cell line, media was supplemen-
ted with 0.5mgml 1 of zeocin (Invitrogen). For calculation of cell
doubling times in low-serum conditions, 2% serum was used.
RT–PCR
Independent samples were taken from cell lines for analysis. RNA
was extracted from snap-frozen cell pellets using the mirVana
miRNA Isolation kit (Invitrogen), following the manufacturers’
instructions. After extraction, 1 mg of each RNA sample was treated
with 2U DNAse and incubated at 37 1C for 15min followed by
10min at 65 1C. cDNA synthesis was carried out using the
Revertaid cDNA synthesis kit (Fermentas, St Leon-Rot, Germany).
Briefly, 500 ng of RNA was incubated with 200U reverse
transcriptase and 500 ng of OligodT primer at 42 1C for 1 h
followed by 70 1C for 5min. Twenty units of RiboLock RNase
inhibitor was also included in the reaction mix.
Primers used for PCR are displayed in Table 1. One microliter of
cDNA was incubated with 1 Biomix Red, and forward and
reverse primers (1 nM) in a final volume of 10 ml. The PCR
conditions were: 95 1C for 10min followed by 40 cycles of 95 1C for
30 s, optimised primer annealing temperature for 1min and 72 1C
for 1min. Products were visualised by electrophoresis through a
2% agarose gel at 120V for 30min. For primers using a touchdown
programme the annealing temperature was decreased by 1 1C each
cycle for the first 10 cycles, starting from 65 1C. GAPDH was used
as a housekeeping gene in all experiments.
Quantitative PCR
Quantitative PCR reactions were carried out as previously
described (Rogers et al, 2012). Primer sequences and optimised
annealing temperatures are given in Table 1. Three independent
cDNA samples from each cell line were used for each analysis. Data
was normalised using Gapdh. Relative expression compared to one
C17.2 cDNA sample was calculated using the Pfaffl equation (Pfaffl,
2001).
Table 1 Primers and optimised annealing temperatures for RT–PCR and qPCR
Primer Forward sequence (50–30) Reverse sequence (50–30) Annealing temperature (1C)
Wnt1 CGACCTCGTCTACTTCGAG ACCAGTGGAAGGTGCAGTTG 58
Axin2 CGCTCGGGTTTGTGTTAAGT GAGAGCTGGAGCCCTCAATA 58
Myc CCCCAAGGTAGTGATCCTCA TCCAGCTCCTCCTCGAGTTA 61
Ngfr CCTTGTGCTCGGTGGTATTT AGAGACCCCCAGAACCAAAC 58
Ntrk1 AGAGCGATGTGTGGAGCTTT TGATGGCGTAGACATCAGGA TD 65–55
Atoh1 GACCCGCATTGGGTACTTTA TGCATTGGCAGTTGAGTTTC 58
Cntn2 CTGGTTTTCTCGGGTGTGAT GGGTCTTTTGCTGGGACATA 58
Sox2 AAGGGTTCTTGCTGGGTTTT TGCCTTAAACAAGACCACGA 61
Lhx2 CTGCCACCTGGGCATCTC AAGTGCAAGCGGCAATAGAC TD 65–55
Meis1 TTATACCCAAGCCCAGATGC ACTCATTGTCGGGTCTCCTG 60
Calb1 AGAAACGGCCAGAAACAGAA TTGCCAAGAATCCAGAAACC 58
Ptf1a CTTGCAGGGCACTCTCTTTC CGATGTGAGCTGTCTCAGGA 58
Gapdh ATGTTCGTCATGGGTGTGAA GTCTTCTGGGTGGCAGTGAT 58
Abbreviation: TD¼ touchdown.
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Immunofluorescence
Cells were fixed by incubating with 4% PFA for 20min. Cells were
washed 3 5min in PBST (PBS, 0.1% Tween). Cells were
permeabilised and blocked in 5% normal goat serum (NGS,
Invitrogen) and 0.25% Triton X-100 in PBS at room temperature
for 1 h. Cells were washed in PBST for 3 5min. Primary
antibodies were prepared in 2% NGS and 0.1% Triton X-100 in
PBS. Cells were then incubated with the primary antibody at 4 1C
overnight. The following antibodies were used; mouse anti-b-
catenin (1 in 200, 2677 Cell Signaling Technology, Danvers, MA,
USA) and rabbit anti-TUJ1 (1 in 500, Covance, Harrogate, UK).
Cells were washed 3 5min in PBST then incubated with the
appropriate secondary antibody; Alexa Fluor 555 goat anti-mouse
(1 in 500, Invitrogen) or Alexa Fluor 488 goat anti-rabbit antibody
(1 in 500, Invitrogen) at room temperature for 1 h in the dark.
After three further washes in PBST, cells were mounted using
Vectashield containing 40,6-diamidinophenylindole (Vector
Laboratories, Peterborough, UK). Images were obtained using a
Leica DMRM fluorescent microscope (Nikon, Digital sight-USB
(H), Kingston upon Thames, UK) equipped with a Nikon digital
camera. NIS elements software was used to capture images
(Nikon).
Western blot
Western blotting was carried out as previously described (Levesley et al,
2011). Membranes were incubated with primary antibodies to Wnt1
(1 in 500, Abcam, Cambridge, UK), Ngfr (1 in 1000, Cell Signaling
Technology) and Gapdh (1 in 100, Abcam) for 1h at room temperature.
Intracranial injection of cells into rats
Adult male Sprague-Dawley rats were housed with libitum access
to food and water at a 12-h light/dark cycle. Animals were treated
according to the guidelines of the European Community and local
ethics committee. The animals were immune suppressed using
cyclosporine A (10mg kg 1 per day). Cells at 85–90% confluence
were prepared for transplantation and stored on wet ice. Animals
were anesthetised with isofluorane (1–2.5% in an oxygen/70%
nitrous oxide mixture) and stereotaxically injected with 1 ml of cell
suspension (200 000 cells ml 1) at two sites directly overlying the
substantia nigra. Cells were injected slowly through a 22-guage,
10ml Hamilton syringe, and the needle was left in place for 2min
after completion of injection. For each cell line, four animals were
transplanted. After 8 weeks, brains were excised. Frozen sections
were cut and stained with haematoxylin and eosin for subsequent
review by a pathologist.
Immunohistochemistry
The following antibodies were used; rabbit anti-Ki-67 (SP6) (1 in
200, Neomarkers, Fremont, CA, USA), rabbit anti-b-catenin (1 in
250, 9582 Cell Signaling Technology) and rabbit anti-Myc (1 in
100, Abcam). Antigen retrieval was performed by incubating
sections in sodium citrate buffer (pH 6) in a steamer for 40min.
Endogenous protein was blocked by incubating with 5% NGS for
10min. Sections were then incubated with a peroxidase block
(Dako, Ely, UK) for 5min. Ki-67 and b-catenin antibodies were
incubated at 4 1C overnight. Myc antibody was incubated for 1 h at
room temperature. Detection was undertaken using the EnVision
detection system peroxidase/DAB (Dako). Stained sections were
reviewed by a pathologist.
Electron microscopy
Frozen sections were fixed in 2.5% glutaraldehyde in cacodylate
buffer for 24 h followed by 1% osmium tetroxide for 1 h. This was
followed by standard EM processing using TAAB TER resin, then
inverting a resin-filled capsule over the section on the slide before
polymerisation at 65 1C overnight. The subsequent resin block
containing the section was removed from the glass slide and
trimmed. A 0.5-mm section was cut using a Leica UM7
ultramicrotome before staining with toluidine blue in 1% borax
(Leica Microsystems, Milton Keynes, UK). Slides were examined
using a light microscope and an area selected for electron
microscopy. Eighty nanometer sections were cut from the selected
area and mounted on a copper grid and stained with uranyl acetate
in ethanol followed by lead citrate. The stained sections were
examined in a JEOL 1010 transmission electron microscope at
100KV and appropriate images recorded using an integrated
digital camera system (Olympus-SIS, Munster, Germany).
RESULTS
Construction of a cerebellar progenitor cell line with stable
WNT/b-catenin pathway activation
We used a cerebellar progenitor cell line (C17.2) immortalised by
stable expression of Myc (Snyder et al, 1992) to investigate the role
of the WNT/b-catenin pathway activation in medulloblastoma.
Pathway activation was induced by constructing a cell line with
stable expression of Wnt1. Wnt1 cDNA was cloned into the pCA-
EGFP vector and then transfected into the C17.2 cells. Multiple
clones of cells were isolated. The stable Wnt1-expressing cell line
(C17.2-Wnt1) selected for further analysis did not show abnormal
morphology or cell growth rate compared with the other Wnt1
lines. Stable Wnt1 expression was confirmed by RT–PCR and
western blot (Figures 1A and B). No Wnt1 gene or protein
expression was seen in the original C17.2 line.Myc gene expression
was retained in the C17.2-Wnt1 cell line with no significant
difference in expression level compared with C17.2 (Figure 1C).
The morphology of C17.2-Wnt1 was slightly altered relative to
C17.2. The C17.2 cell line changed in appearance during culture,
sometimes looking epithelial (Figure 1D) and sometimes display-
ing cell processes (Figure 1E). The C17.2-Wnt1 line looked
uniformly epithelial with a more rounded cell shape compared
with C17.2 (Figure 1F). To demonstrate Wnt1 expression activated
the WNT/b-catenin pathway, we initially looked at the expression
of the pathway target Axin2 by RT–PCR. Expression was only seen
in the C17.2-Wnt1 line (Figure 1A). We also analysed the intra-
cellular location of b-catenin. Upon pathway activation, b-catenin
is stabilised and translocates to the nucleus to induce transcription
of target genes. Nuclear localisation of b-catenin was only seen in
C17.2-Wnt1 (Figure 1G).
Functional effect of WNT/b-catenin pathway activation
We investigated the functional effect of WNT/b-catenin pathway
activation in vitro to try to gain an understanding of what role
pathway activation is playing in tumorigenesis. We investigated
cell proliferation by calculating doubling times in low- and high-
serum conditions. However, we found no significant difference
between the two cell lines (data not shown). We also investigated
cell migration using a scratch assay but again saw no difference in
the presence or absence of WNT/b-catenin pathway activation
(data not shown).
We looked at the cells’ ability to undergo neuronal differentia-
tion by culturing the cells in differentiation media, containing
NGF. After 1 day, C17.2 cells differentiated into neurons. However,
even after 7 days, the C17.2-Wnt1 cell line had not differentiated
(Figures 2A–D). We investigated this further by staining fluores-
cently for the neuronal marker beta-tubulin (Tuj1). C17.2 cells
grown in normal or differentiation culture media displayed
expression of Tuj1, with the differentiated cells displaying a higher
WNT/b-catenin pathway in medulloblastoma
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intensity signal. The C17.2-Wnt1 cells displayed no staining under
either condition (Figure 2E).
To investigate further the role the WNT/b-catenin pathway is
having in the decision to undergo differentiation, we investigated
the expression of a number of genes involved in neuronal
differentiation. To stimulate differentiation in culture, we used
NGF. We therefore looked at the expression of the two receptors of
this protein; Ngfr and neurotrophic tyrosine kinase receptor type 1
(Ntrk1). Gene expression of Ntrk1 was not seen in either cell line
(data not shown). Nerve growth factor receptor (Ngfr) gene
expression was seen in C17.2; however, expression was decreased
in C17.2-Wnt1 (Figure 2F). Nerve growth factor receptor (Ngfr)
protein expression was seen in C17.2 but was lost in C17.2-Wnt1
(Figure 2G).
Cells with WNT/b-catenin pathway activation form
tumours in vivo
C17.2 and C17.2-Wnt1 cells were injected orthotopically into
immunosupressed rats. As previously published (Snyder et al,
1992), C17.2 cells did not form tumours. However, with induced
WNT/b-catenin pathway activation (C17.2-Wnt1 cells), tumours
rapidly formed after 4 weeks. All four rats transplanted with C17.2-
Wnt1 cells developed tumours. Histologically, tumours resembled
primitive neuroectodermal tumours (PNETs), consistent with the
appearance of classical medulloblastoma. Tumours were well
circumscribed with no infiltration into the surrounding brain
tissue (Figures 3A and B). Ki67 staining revealed a high
proliferation rate similar to that seen in medulloblastoma
(Figure 3C). b-Catenin staining revealed nuclear localisation of
the protein, suggesting the WNT/b-catenin pathway was active
in vivo, as well as in vitro (Figure 3D). Tumours also displayed
Myc protein expression (Figure 3E). Electron microscopy was used
to look for features of differentiation. Very few features of
neuronal differentiation such as neurosecretory vesicles were seen,
consistent with a PNET (Figures 3F and G). Our results demon-
strated that cerebellar progenitor cells with stable Myc expression
and WNT/b-catenin pathway activation became tumorigenic.
C17.2 cells express stem cell markers of the cerebellar VZ
To investigate the cell of origin of medulloblastomas with WNT/b-
catenin pathway activation, we looked at what cell type C17.2 cells
resemble. We analysed the expression levels of genes that have
been linked to different cerebellar progenitor cell types using RNA
extracted from cells grown in normal or differentiation media
using RT–PCR. For granule cell progenitors, we investigated Atoh1
and Cntn2 (Ben-Arie et al, 1997; Backer et al, 2002; Bizzoca et al,
2003), whereas ptf1a,Meis1 and Lhx2 were used as markers of cells
in the cerebellar VZ (Hoshino et al, 2005; Morales and Hatten,
2006; Millen and Gleeson, 2008). We also investigated the neural
stem cell marker Sox2 and the post mitotic marker of Purkinje cells
Calb1 (Wassef et al, 1985).
Expression was only seen for Ptf1a, Meis1 and Sox2, suggesting
the C17.2 cells are more like stem cells found in the VZ than
granule cell progenitors in the RL. Ptf1a expression was seen in a
subset of samples from C17.2 but not in C17.2-Wnt1 (Figure 4A).
During culture, the appearance of C17.2 varied sometimes
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Figure 1 Characterisation of C17.2 and C17.2-Wnt1 cell lines. Wnt1 gene and protein expression was confirmed in C17.2-Wnt1 by RT–PCR and
western blot, respectively (A and B). WNT/b-catenin pathway activation in C17.2-Wnt1 was confirmed by Axin2 expression. Expression of the WNT/b-
catenin pathway target Axin2 was only seen in the C17.2-Wnt1 line (A). The housekeeping gene Gapdh demonstrated similar gene and protein expression
levels in both C17.2 and C17.2-Wnt1 (A and B). Three repeats generated from independent samples are displayed for each cell line; C1, C2 and C3 from
C17.2 and W1, W2, W3 from C17.2-Wnt1. Myc gene expression was not altered after Wnt1 expression in the C17.2 cell line as measured by qPCR (C).
Stable overexpression of Wnt1 altered the morphology of the cells. The appearance of C17.2 was sometimes epithelial (D) and sometimes displayed cell
processes (E). C17.2-Wnt1 was uniformly epithelial with a more rounded cell shape compared with C17.2 (F). The cellular location of b-catenin was
investigated using immunofluorescence. In C17.2, only membrane and cytoplasmic staining of b-catenin was seen. In C17.2-Wnt1, nuclear staining, indicating
pathway activation, was also seen (G). Abbreviation: Neg¼ negative control.
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appearing more differentiated and sometimes more epithelial. This
variation may have influenced when Ptf1a expression was seen.
Meis1 and Sox2 expression was seen in all samples analysed from
both cell lines. Quantitative PCR revealed that Meis1 displayed a
similar level of gene expression in both cell lines (Figure 4B). Sox2
gene expression was four-fold higher in C17.2 compared with
C17.2-Wnt1 (Figure 4B). No expression was seen for Atoh1 or
Cntn1, suggesting, in this model, the cells generating tumours did
not resemble granule cell progenitors.
DISCUSSION
We have generated a cell line with the means to orthotopically
model medulloblastoma with WNT/b-catenin pathway activation.
Previous studies have demonstrated that tumours with WNT/b-
catenin pathway activation account for 25% of medulloblastomas.
However, the role pathway activation is playing in the develop-
ment of these tumours is not understood. Therefore, it is
important to generate models that can be used to study the
pathology of this disease and as a resource for developing and
testing new treatments. We provide evidence of the role the WNT/
b-catenin pathway may be having in medulloblastoma. Our data
suggest pathway activation is contributing to tumorigenesis by
inhibiting neuronal differentiation of progenitor cells therefore
maintaining them in a proliferative and more ‘stem-like’ state.
Aberrant activation of the WNT/b-catenin pathway in a subset
of medulloblastomas has been demonstrated in a number of
studies (Ellison et al, 2005; Clifford et al, 2006; Thompson et al,
2006; Rogers et al, 2009). However, the biological effect of
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50 m
100 m 100 m 100 m 100 m
50 m 50 m
50 m 50 m 50 m
50 m 50 m 50 m
50 m 50 m 50 m
C17.2 GM
C17.2 DM
C17.2-Wnt1 GM
C17.2-Wnt1 DM
C1 C2 C1 C2C
3
Ngfr
Gapdh
Ngfr
Gapdh
W
1
W
1
W
2W
2
W
3
N
eg
DAPI Merged
Figure 2 WNT/b-catenin pathway activation inhibits neuronal differentiation. Cells were grown in normal growth media (GM) or differentiation media (DM).
After 1 day in DM, C17.2 cells lost the epithelial morphology seen when in GM (A) and gained a neuronal appearance (B). C17.2-Wnt1 retained the same
appearance in GM (C) or DM (D) with no evidence of neuronal differentiation. C17.2 cells displayed some TUJ1 staining in GM with an increased intensity of
staining when the cells underwent neuronal differentiation in DM. C17.2-Wnt1 cells displayed no TUJ1 staining under growth or differentiation conditions (E).
Nerve growth factor receptor (Ngfr) gene expression was analysed in three independent samples from C17.2 and C17.2-Wnt1 by RT–PCR. Nerve growth
factor receptor expression was seen in C17.2 (C1–C3). No expression or a very low level of expression was seen in C17.2-Wnt1 (W1-W3) (F). Expression of
the housekeeping gene Gapdh was seen in all samples. Nerve growth factor receptor protein expression, measured by western blot, was seen in C17.2
(C1, C2) but lost in C17.2-Wnt1 (W1, W2) (G). Protein expression of Gapdh was seen in all samples. Abbreviation: Neg¼ negative control.
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pathway activation and how this influences tumorigenesis is
still unknown. Pathway activation in medulloblastoma has also
been shown to be associated with a better prognosis, suggesting it
is a disadvantage to the tumour (Ellison et al, 2005; Gajjar et al,
2006). However, we hypothesised that the pathway is involved in
the development of medulloblastoma and that therefore the
reason for the association with a better prognosis is that this
subgroup is less aggressive or more susceptible to current
treatments than other medulloblastomas with different molecular
aberrations.
We demonstrated that WNT/b-catenin pathway activation in
cerebellar progenitor cells caused the cells to form tumours in vivo
that histologically resembled classical medulloblastoma, confirm-
ing our hypothesis that pathway activation is involved in
tumorigenesis. In our model, pathway activation may be working
in conjunction with Myc, as the gene is stably expressed in the
C17.2 cell line and protein expression was retained in tumours
generated in vivo. Previously reported data has shown that MYC
expression is seen in medulloblastomas with WNT/b-catenin
pathway activation (Kool et al, 2008; Northcott et al, 2011),
suggesting our model is representative of this clinical subgroup.
Analysis of previously published medulloblastoma expression
array data ((GSE10237) (Kool et al, 2008)) demonstrated that
tumours with WNT/b-catenin pathway activation displayed a
significantly higher level of Myc expression compared with the rest
of the tumours (P¼ 0.006), suggesting the two may cooperate in
patient tumours (Supplementary Figure 1). In a mouse model of
CNS PNET, b-catenin mutations alone did not induce tumour
formation. However, in combination with Myc expression and p53
knockout tumours developed (Momota et al, 2008).
In our model, WNT/b-catenin pathway activation inhibited neuronal
differentiation in vitro. The WNT/b-catenin pathway plays a complex
role in CNS development. WNT/b-catenin pathway signals are involved
in the positioning of the cerebellum along the anterior–posterior axis of
the neural tube (Sato et al, 2004). The pathway has also been shown to
influence the decision of neuronal progenitor cells to proliferate or
differentiate. At different developmental stages, pathway activation has
either been shown to stimulate proliferation or differentiation (Chenn
and Walsh, 2002; Viti et al, 2003; Zechner et al, 2003; Israsena et al,
2004). In the majority of studies, pathway activation was found to
stimulate progenitor cell proliferation at early development stages and
neuronal differentiation during later stages (Hirsch et al, 2007). Less is
known about how the WNT/b-catenin pathway specifically affects
progenitor cells in the cerebellum. However, a recent study demon-
strated that WNT/b-catenin pathway activation promoted proliferation
and impaired differentiation of neural stem cells in the developing
cerebellum (Pei et al, 2012).
Figure 3 C17.2-Wnt1 cells formed tumours in vivo. Hematoxylin and eosin staining shows a tumour similar in appearance to a PNET. Tumours were well
circumscribed with no infiltration into the surrounding brain tissue (A and B). Ki67 staining revealed a proliferation rate in the tumours similar to those seen
in medulloblastoma (C). Nuclear localisation of b-catenin was seen in the tumours, indicating WNT/b-catenin pathway activation (D). Tumours
also displayed myc protein expression (E). Electron microscopy revealed very few features of differentiation such as neurosecretory vesicles (red arrow)
(F and G). Features were consistent with a PNET.
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Figure 4 Gene expression of cerebellar progenitor markers. Expression
was analysed in samples extracted from cells grown in normal growth
media (C17.2; C1-4, C17.2-Wnt1; W1-4) and cells grown in differentiation
media (C17.2; Cd1-2, C17.2-Wnt1; Wd1-2). Ptf1a expression was seen in
a subset of C17.2 cells measured by RT–PCR (A). Expression of the
housekeeping gene gapdh was seen in all samples. Meis1 and Sox2
expression was seen in all samples analysed from both cell lines.
Quantitative PCR revealed equal expression of Meis1 in C17.2 and
C17.2-Wnt1 cell lines. Sox2 displayed four-fold higher expression in C17.2
compared with C17.2-Wnt1 (B). Abbreviation: Neg¼ negative control.
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Our data suggest the C17.2 cell line is derived from progenitor
cells at a stage in development when they are prevented from
differentiating in response to WNT/b-catenin pathway signals.
These findings suggest that activation of WNT/b-catenin pathway
in our model may be causing tumour formation by preventing
differentiation and maintaining the cells in a more primitive,
proliferating state. We saw no difference in the rate of proliferation
between C17.2 and C17.2-Wnt1 cells. This may be due to the fact
that the C17.2 cell line was originally immortalised using Myc. We
suggest that myc stimulates proliferation of the cells and WNT/b-
catenin pathway activation prevents the cells from responding to
signals to differentiate. Similarly, in a mouse model of CNS PNET,
induced by WNT/b-catenin pathway activation in conjunction
with Myc expression and p53 knockout, tumours displayed regions
of differentiation, but not in cells displaying nuclear b-catenin,
indicating pathway activation inversely correlated with differentia-
tion (Momota et al, 2008).
Analysis of medulloblastoma expression array data revealed that
genes displaying differential expression between the WNT/b-
catenin pathway subgroup and other medulloblastomas included a
number of genes linked to neuronal differentiation. This included
upregulation of the fetal growth factor FGF20 and the epidermal
growth factor receptor ERBB2, and downregulation of the neuronal
marker MAP2 in the WNT subgroup (Kool et al, 2008; Northcott
et al, 2011). Additionally, a recent study has shown increased
expression of neuronal markers in medulloblastoma xenografts
treated with drugs that can inhibit the WNT/b-catenin pathway
(Cimmino et al, 2012).
We saw a downregulation of Ngfr expression in C17.2-Wnt1
cells compared with C17.2. Nerve growth factor can bind to two
different cell receptors; NGFR and the tyrosine kinase NTRK1.
Signalling through NGFR has been shown to stimulate many
different responses including survival, differentiation and apopto-
sis (Friedman, 2000; Lee et al, 2001; Dechant and Barde, 2002;
Lu et al, 2005). Nerve growth factor receptor is highly expressed on
neurons and glia during CNS development (Cragnolini and
Friedman, 2008). Neonatal NGFR-positive neural stem cells have
been shown to have neurogenic potential that was enhanced by
treatment with neurotrophins including NGF. However, this
enhancement was not seen using stem cells from NGFR / mice
(Young et al, 2007). Nerve growth factor receptor is expressed in
the developing cerebellum; however, its’ role is not fully under-
stood (Barnes et al, 2009).
Nerve growth factor receptor expression has also been seen in
medulloblastoma. However, expression was not seen in medullo-
blastomas with WNT/b-catenin pathway activation (Kool et al,
2008; Barnes et al, 2009). Analysis of previously published mRNA
array expression data ((GSE10237) (Kool et al, 2008)) demon-
strated WNT subgroup tumours displayed a low level of NGFR
expression compared with the rest of the tumour cohort
(Supplementary Figure 2). Nerve growth factor receptor expression
has also shown higher expression in desmoplastic compared with
classic medulloblastoma (Buhren et al, 2000; Kuchler et al, 2011).
Consistent with these histological findings, WNT/b-catenin path-
way activation has more frequently been seen in classic
medulloblastomas and sonic hedgehog (Shh) pathway activation
in desmoplasic tumours (Thompson et al, 2006).
No expression of the second receptor to NGF, Ntrk1, was seen in
C17.2 or C17.2-Wnt1. Therefore, a loss of Ngfr expression in
C17.2-Wnt1 means they lack any receptor to respond to NGF
signals, which may explain the lack of neuronal differentiation
seen in response to NGF treatment. As far as we are aware there is
no evidence in the literature linking the WNT/b-catenin pathway
to NGFR expression. Further investigation is needed to determine
if the downregulation of expression seen in the C17.2-Wnt1 cells is
a direct consequence of WNT/b-catenin signalling.
There has been much debate about the cell of origin of
medulloblastoma. In the cerebellum, there are two distinct zones of
progenitor cells; the VZ and the RL. The main type of cells
generated from the RL are granule neurons with the majority of
other cell types arising from the VZ (Hatten and Roussel, 2011).
Medulloblastomas have been suggested to arise from granule cell
precursors. However, genomic and expression data from medullo-
blastomas suggested that not all subtypes arise from these cells
(Gilbertson and Ellison, 2008; Sutter et al, 2010). A more current
interpretation proposes that medulloblastomas with WNT/b-
catenin pathway activation may arise from progenitor cells in
the VZ. In support of this hypothesis, aberrant activation of the
WNT/b-catenin pathway induced proliferation and inhibited
differentiation of neural stem cells from the cerebellar VZ but
not granule progenitor cells (Pei et al, 2012). In a separate study,
selected depletion of adenomatous polyposis coli in ATOH1-
expressing cells lead to a decrease in cell proliferation and
premature differentiation of cerebellar granule cells (Lorenz et al,
2011).
The lack of expression of granule cell markers Atoh1 and Cntn2
in both the C17.2 and C17.2-Wnt1 lines suggests the C17.2 cells did
not resemble this lineage. The bHLH factor Ptf1a is essential for
the generation of GABAergic neurons from the cerebellar VZ
(Hoshino et al, 2005). C17.2 cells demonstrated expression of
Ptf1a, suggesting the cells resembled VZ cells more than granule
cell progenitors. This was supported by the expression of Meis1,
which has been shown to be expressed by cells in the VZ (Morales
and Hatten, 2006). The original C17.2 cell line was developed from
cerebella of newborn mice (P4) (Ryder et al, 1990). At this stage of
development, dividing granule cell progenitors are present in the
RL. Neural stem cells, which originated in the VZ, are also present
in the white matter (Lee et al, 2005). Therefore, the C17.2 line
could have been generated from the neural stem cells rather than
granule progenitor cells. However, it cannot be discounted that the
immortalisation of the C17.2 cells with Myc may have affected the
phenotype of the original cells the line was derived from, as Myc
also plays a role in normal neuronal development (Hatton et al,
2006; Wey et al, 2010). It has also previously been demonstrated
that immortalisation of granule cell precursors with SV40 T
antigen caused the cells to lose their restricted fate and gain an
ability to differentiate into multiple cell types (Gao and Hatten,
1994). Hence, it cannot be discounted that the original cells the
C17.2 line was generated from could have been granule progenitor
cells that were altered by Myc immortalisation.
The gene expression of cerebellar markers seen in C17.2 and
C17.2-Wnt1 cells reflects what is seen in WNT subgroup
medulloblastomas ((GSE10237) (Kool et al, 2008)). High Atoh1
and Cntn2 expression was seen in Shh sub-group tumours, but not
in the WNT/b-catenin group. Meis1 expression was seen in both
WNT and Shh groups. Sox2 displayed higher expression in the Shh
group (Supplementary Figure 3). Ptf1a data was not available.
In the study by Gibson et al (2010), tumours resembling
medulloblastoma were generated in mice with mutated b-catenin
and p53 knockout. In this model, no tumours developed from
cerebellar progenitors but instead arose from brain stem
progenitor cells found in the lower RL. This region lines the
ventral region of the fourth ventricle, with the cerebellum located
on the dorsal side. They also found that the normal migration and
differentiation of these cells was impaired in the tumour model,
agreeing with the inhibition of neuronal differentiation we saw in
our study. In the model developed by Gibson et al, tumours
developed from a combination of WNT/b-catenin pathway
activation and TP53 knockout in contrast to our model, where
Myc expression was used which may explain why they did not see
tumours develop from cerebellar progenitor cells. In addition,
considering the complex role the WNT/b-catenin pathway has in
CNS development, the timing of induced pathway activation may
be important in determining where tumours arise. In a recent
study, a transient increase in proliferation and disruption of
normal cerebellar development occurred in neural stem cells from
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the cerebellar VZ when the WNT/b-catenin pathway was
aberrantly activated, suggesting at least some WNT subgroup
tumours may develop from cerebellar progenitors (Pei et al, 2012).
In conclusion, we have developed a cell line that provides the
means to orthotopically model WNT/b-catenin pathway-activated
medulloblastoma. We suggest that inhibition of progenitor cell
differentiation, therefore maintaining them in a proliferative and
more ‘stem-like’ state, is the mechanism by which pathway
activation is involved in tumorigenesis, which in turn may be
achieved through downregulated expression of NGFR. This
evidence suggests pathway activation is playing a key role in
tumour development and is therefore an important treatment
target for this subset of medulloblastomas. Our data also
demonstrates that progenitor cells expressing stem cell markers
of the cerebellar VZ have the potential to develop tumours that
resemble medulloblastoma. As tumours with WNT/b-catenin
pathway activation account for 25% of medulloblastomas, under-
standing how the pathway is involved in tumorigenesis is
important. This model can be used as a resource for future
analysis of the role the pathway is playing in tumorigenesis and
also for the development and testing of targeted therapies.
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